CN104480215A - Gene joint detection method and kit - Google Patents

Gene joint detection method and kit Download PDF

Info

Publication number
CN104480215A
CN104480215A CN201410849552.XA CN201410849552A CN104480215A CN 104480215 A CN104480215 A CN 104480215A CN 201410849552 A CN201410849552 A CN 201410849552A CN 104480215 A CN104480215 A CN 104480215A
Authority
CN
China
Prior art keywords
gene
pcr
probe
detection method
braf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410849552.XA
Other languages
Chinese (zh)
Other versions
CN104480215B (en
Inventor
唐涛
周细武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanning Wilke Biotechnology Co., Ltd.
Original Assignee
NINGBO UNIGENEDX BIO-PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NINGBO UNIGENEDX BIO-PHARMACEUTICAL Co Ltd filed Critical NINGBO UNIGENEDX BIO-PHARMACEUTICAL Co Ltd
Priority to CN201410849552.XA priority Critical patent/CN104480215B/en
Publication of CN104480215A publication Critical patent/CN104480215A/en
Application granted granted Critical
Publication of CN104480215B publication Critical patent/CN104480215B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a joint detection method for gene mutation. The joint detection method is characterized in that 16 gene mutations, including KRAS (Kirsten rat sarcoma viral oncogene homolog), PIK3CA (phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha), BRAF (B-Raf proto-oncogene, serine/threonine kinase) and EGFR (Epidermal Growth Factor Receptor) genes can be detected synchronously by using 20-50ng of DNA as a sample. The method comprises the steps of designing a specific probe; building a reaction system for an MLPA (Multiplex Ligation Dependent Probe Amplification) mutant gene sequences; largely amplifying the targeted gene sequences by PCR (Polymerase Chain Reaction). The joint detection method for gene mutation has the advantages that the specificity is high, and 10-100ng of wild type DNA do not generate nonspecific interference signals; the selectivity is outstanding, and 0.1 to 1.0% of mutation can be detected under the background of 99-99.9% of wild type DNA.

Description

A kind of gene association detection method and test kit
Technical field
The present invention relates to biology field, be specifically related to a kind of method of joint-detection transgenation, particularly one is with MLPA method for technology platform, detects KRAS, PIK3CA, BRAF and EGFR gene 16 kinds of methods of suddenling change altogether simultaneously.
Background technology
RAS gene comprises KRAS, HRAS and NRAS tri-kinds, the mainly KRAS gene relevant to lung cancer, be positioned on No. 12 karyomit(e)s, coding P21 albumen, affect the mcroorganism molecule syntheses such as intracellular nucleic enzyme by acceptance and transfer cell outgrowth stimulus signal, and then the growth and differ entiation of cell is regulated and controled.When No. 2,3, KRAS gene extron is undergone mutation, the KRAS gene of sudden change can sustained activation RAF-MEK-ERK-MAPK signal transduction pathway, causes undesired cell proliferation, differentiation and regulation and control disorderly.In the tumours such as leukemia, lung cancer, large bowel cancer and carcinoma of the pancreas, all found that KRAS gene has higher mutation rate.
Phosphatidyl-inositol 3-kinase (phosphatidylinositol-3-kinase, PI3K) is an important signal transduction pathway molecule, regulates subunit p85 to form by a catalytic subunit p110 and.3 hypotypes such as I type, II type and III type can be divided into according to the p110 constructional feature of PI3K is different with substrate molecule.The signal transduction pathway of PI3K mediation plays an important role in the generation of the propagation of cell, conversion, apoptosis and tumour, the propagation of regulate tumor cell and survival.Research finds, the imbalance of PI3K-AKT signal path can cause the generation of the malignant tumours such as lung cancer, ovarian cancer, breast cancer, glioblastoma, carcinoma of endometrium and nasopharyngeal carcinoma.
BRAF is one of most important proto-oncogene of the mankind, and BRAF sudden change occurs the human tumor of about 8%.BRAF the overwhelming majority sudden change occur in BRAF protein kinase active region or its near, wherein about 70% ~ 90% is that the 1799th Nucleotide T of BRAF gene exons 15 sports A, and the α-amino-isovaleric acid causing it to encode is replaced (namely BRAF V600E suddenlys change) by L-glutamic acid.BRAF gene is positioned at No. 7 karyomit(e)s, it is the serine/threonine kinase in cell mitogen element former activated protein kinase (MAPK) signal path, once this genetic expression changes, biological function will be made to get muddled, thus the signal path making it mediate imbalance also finally cause cell transformation even to be cancerated.
EGF-R ELISA (EGFR) is a kind of tyrosine kinase receptor (RTK), is positioned at No. 7 karyomit(e), is made up of 28 exons, and 1186 amino acid of encoding, its glycoprotein molecule amount is about 170kDa.EGFR is one of I type tyrosine kinase acceptor gene family member, is that transfer cell external signal is to endonuclear important channel albumen.The key signal transduction approach of EGFR has: RAS-RAF-MEK-ERK-MAPK path, PI3K-PDK path, PLC-γ path, JAK-STAT path etc.By these approach, extracellular signal is converted into intracellular signal, thus successfully manages extraneous token stimulus, regulate the growth of cell, propagation, differentiation, the apoptosis of T suppression cell.On front four exons that the sudden change of EGFR mainly occurs in TK region in born of the same parents (18 ~ 21), the TK region mutagenesis found at present has kind more than 30.Classical sudden change or hot spot mutation are again in alternative sudden change (L858R) wherein on the deletion mutantion (delE746-A750) of exons 19 and exon 21, account for 90% of sudden change.In addition the alternative mutation T 790M occurred on extron 20 is medicament-resistant mutation, in Molecular Detection, have important reference value equally.
Multiplex ligation-dependent probe amplification (multiplex ligation-dependent probeamplification, MLPA) is a kind of Multiple detection technology of carrying out quantitative and semi-quantitative analysis for DNA sequence dna to be checked first reported by Schouten etc.In MLPA reaction, each target sequence that increases needs a pair probe, and each probe comprises one section of primer sequence and one section of specific sequence.After this pair probe and target sequence are hybridized, then be connected to become an oligonucleotide chain with ligase enzyme.Ligation high special, only have when two probes and target sequence are hybridized completely, i.e. target sequence and probe-specific sequence complete complementary, two sections of probes could be connected into a complete single nucleic acid strands by ligase enzyme; Otherwise, if target sequence and probe sequence are not exclusively complementary, even if only have the difference of a base, also can cause hybridization not exclusively, ligation cannot be carried out.After ligation completes, to increase the probe connected with a pair universal primer, the length of the amplified production of each probe is unique, and scope is between 130 ~ 480bp.MLPA technology can be used for Multiple detection, by rational probe design, can detect multiple target sequence in primary first-order equation simultaneously.When adopt capillary electrophoresis amplified production is separated, analyze, the target sequence simultaneously detected can reach 45.Multiple detection method is conducive to improving detection efficiency, reduces the usage quantity of template, is particularly useful for the few and situation that target spot to be measured is more of template amount.If the target sequence origination point sudden change detected or disappearance, amplification sudden change, so the amplified peak of correspondent probe just can lack, reduces or increase, therefore, just can judge whether target sequence has the exception of copy number or point mutation existence according to the change of amplified peak.
Before formulation clinical treatment, application molecular diagnostic techniques detects each transgenation state in patient's tumour cell exactly, thus select suitable target therapeutic agent, be that application targeted drug carries out prerequisite and the basis of personalized treatment to cancer, the prognosis that simultaneously also can be clinical judge patient is offered help.The special targeted drug for EGFR, PIK3CA, BRAF enters Clinical practice at present, and for the targeted drug of KRAS also in research and development.In lung cancer patient, KRAS, PIK3CA, BRAF and the modal mutant form of EGFR gene have 16 kinds, if use the method for quantitative fluorescent PCR to detect, then need a large amount of clinical samples, not only add the difficulty of clinical sampling, also make patient pay higher testing cost.In order to reduce the usage quantity of clinical sample, simplify and detect operation, the invention provides a kind of based on MLPA technology, efficiently, highly sensitive detection method, KRAS, PIK3CA, BRAF and EGFR gene totally 16 kinds of sudden changes can be detected, for clinical individual medication provides foundation in the DNA sample of 20-50ng simultaneously.
Summary of the invention
In order to improve Clinical Laboratory ability, now provide a kind of based on MLPA technology, the methods that can detect the 16 kinds of sudden changes altogether of KRAS, PIK3CA, BRAF and EGFR gene simultaneously, the method can detect 16 kinds of sudden changes in the DNA sample of 20-50ng simultaneously.
Technical scheme of the present invention comprises following steps:
1. detect gene mutation site
According to wildtype gene sequence and the corresponding mutated genes sequence of No. 2, mankind KRAS gene, 3 exons, design multipair specific probe, detect the catastrophe in following site:
According to wildtype gene sequence and the corresponding mutated genes sequence of No. 9, mankind PIK3CA gene, 20 exons, design multipair specific probe, detect the catastrophe in following site:
According to wildtype gene sequence and the corresponding mutated genes sequence of mankind's BRAF gene 15 exon, design specific probe, detect BRAF V600E sudden change.Namely the 1799th Nucleotide T of 15 exons sports A, and the α-amino-isovaleric acid causing it to encode is replaced (Cosmic ID 476) by L-glutamic acid.
According to wildtype gene sequence and the corresponding mutated genes sequence of No. 19, human EGFR gene, No. 20 and 21 exons, design specific probe, detect alternative sudden change L858R (the Cosmic ID 6224 on the deletion mutantion of 19 exons, 21 exons, alternative mutation T 790M on c.2573T>G) and 20 exons (Cosmic ID 6240, c.2369C>T).
2. probe design process
Need a pair probe to detect target sequence, contain with the complementary district of target sequence strictly complementary in the structure of probe, regulate the fill area of probe length, the guiding region as PCR primer.The primer sequence in PCR primer district can be universal primer or Auele Specific Primer.Can not comprise sudden change in probe or comprise sudden change, mutating alkali yl position within the probe can be positioned at last (when complementary district is positioned at 3 ' end of probe) or first (when complementary district is positioned at 5 ' end of probe).A pair probe is after ligase enzyme connects, and length is between 100 ~ 250nt.
3.19 exon deletion mutantion detection methods
EGFR gene 19 exon easily occur lack region c.2230_2270 designing probe to A, when region c.2230_2270 occur disappearance time cannot amplify strips A; On EGFR gene conserved sequence, designing probe is to B.When not comprising the disappearance in EGFR 19 exon c.2230_2270 region in sample DNA, a certain proportion of A, B two kinds of bands can be amplified.When disappearance containing EGFR 19 exon c.2230_2270 region in sample DNA, the ratio of A band and B band changes, thus judges that EGFR gene 19 exon there occurs deletion mutantion.
4. set up the reaction system of MLPA amplification mutant gene sequence, react a large amount of amplifying target genes sequence by PCR.MLPA reaction system is made up of following reaction:
Template denaturation: added by template DNA in PCR pipe, is placed in PCR instrument, and set temperature is 95 ~ 100 DEG C, maintains 3 ~ 10min, then is cooled to 25 DEG C.
Hybridization: the mixture adding MLPA Buffer and probe in template after denaturing.The concentration of its middle probe is 0.5 ~ 10nM; Containing Tris-HCl (50 ~ 500mM, pH8.2 ~ 9.0) in MLPA Buffer, KCl (2 ~ 5M), MgCl2 (0.5 ~ 5M), EDTA (0.5 ~ 5mM).PCR instrument runs hybridization procedures: 95 DEG C of 1min; 60 DEG C of 16 ~ 24h.
Connect: after hybridization terminates, in each PCR pipe, add ultrapure water and ligase enzyme, PCR instrument runs linker: 50 ~ 58 DEG C of 10 ~ 30min; 95 ~ 100 DEG C of 10 ~ 30min; Be cooled to 20 DEG C.
Pcr amplification: ligation terminates the amplification of laggard performing PCR.In each PCR pipe, add PCR universal primer, dNTPs and Taq enzyme, PCR instrument run PCR program:
Detect: the methods such as agarose electrophoresis, polyacrylamide gel electrophoresis and capillary electrophoresis can be adopted to detect the nucleic acid fragment of amplification.
The invention provides a kind of for detecting the test kits detecting the 16 kinds of sudden changes altogether of KRAS, PIK3CA, BRAF and EGFR gene simultaneously, the specific probe in test kit is in table 1.
Table 1: specific probe sequence table
Described do not comprise sample DNA extraction step based on MLPA technology, the methods that detect the 16 kinds of sudden changes altogether of KRAS, PIK3CA, BRAF and EGFR gene simultaneously, but for fixing the DNA fragmentation that paraffin-embedded sample obtains from formaldehyde, still there is the amplification same with the DNA extracted from fresh tissue sample and detectivity.
Compared with existing detection method, the present invention has following advantage:
(1) detect KRAS, PIK3CA, BRAF and EGFR gene 16 kinds of sudden changes altogether simultaneously;
(2) high specificity, the wild-type DNA of 10 ~ 100ng can not produce nonspecific interference signal;
(3) selectivity is strong, can detect the saltant type of 0.1% ~ 1.0% under the wild-type DNA background of 99 ~ 99.9%;
(4) amount of samples is low, with 20-50ng DNA for sample can detect KRAS, PIK3CA, BRAF and EGFR gene 16 kinds of sudden changes altogether simultaneously.
Accompanying drawing explanation
Fig. 1: embodiment 1 polyacrylamide gel electrophoresis figure
Fig. 2: embodiment 2 polyacrylamide gel electrophoresis figure
Fig. 3: embodiment 3 polyacrylamide gel electrophoresis figure
Embodiment
With specific embodiment, the present invention is described in further detail below.Should be understood that, specific embodiment is only make clearer explanation to the present invention, instead of limitation of the present invention.
Embodiment 1
Respectively get DNA 2 μ L in table 2 as template in PCR pipe, be placed in PCR instrument, set temperature is 95 DEG C, maintains 5min, then is cooled to 25 DEG C.Add 1.5 μ L MLPABuffer and 1.5 μ L Probemix (containing 34 probes in table 1 in Probemix) in template after denaturing, PCR instrument runs hybridization procedures: 95 DEG C of 1min; 60 DEG C of 16h.After hybridization terminates, in each PCR pipe, add 15 μ L ultrapure waters and 0.1 μ L ligase enzyme, PCR instrument runs linker: 54 DEG C of 20min; 95 DEG C of 10min; Be cooled to 20 DEG C.Ligation terminates the amplification of laggard performing PCR.In each PCR pipe, add 1.0 μ LPCR universal primers, 1.0 μ L dNTPs and 0.5 μ L Taq enzyme, PCR instrument run PCR program:
Detected the nucleic acid fragment of amplification by polyacrylamide gel electrophoresis, see Fig. 1.Each catastrophe point is all accurately detected, and the nucleotide fragments length of pcr amplification is consistent with the length of probe.
Table 2: embodiment 1 template DNA
Embodiment 2
Respectively get DNA 2 μ L in table 3 as template in PCR pipe, all the other checked operations, with embodiment 1, are detected the nucleic acid fragment of amplification, see Fig. 2 by polyacrylamide gel electrophoresis.When the DNA extracted in healthy human blood is as sample, pcr amplification goes out two band that length is 186bp and 194bp; And with E746-A750 disappearance HCC827 cell genomic dna for sample time, only amplify the band that length is 194bp.
Table 3: embodiment 2 template DNA
Embodiment 3
Respectively get DNA 2 μ L in table 4 as template in PCR pipe, all the other checked operations, with embodiment 1, are detected the nucleic acid fragment of amplification, see Fig. 3 by polyacrylamide gel electrophoresis.When there is several genes sudden change in sample simultaneously, this method of inspection can out by the gene test of sudden change simultaneously.
Table 4: embodiment 3 template DNA
Embodiment 4
Collect the tumor tissues (comprising flesh tissue and paraffin section) that clinical diagnosis is 57 routine patients of lung cancer, use the DNA extraction kit of Qiagen company and paraffin embedding DNA extraction kit to extract genomic dna as template.All the other checked operations, with embodiment 1, detect the nucleic acid fragment of amplification by capillary electrophoresis.The transgenation situation detected in 57 routine samples is in table 5.
Table 5: Tumor Tissues of Patients with Lung Cancer DNA detection in Gene Mutation result
In addition the sample in embodiment 4 is carried out sequence verification, the detected result of sequencing result and the present embodiment is completely the same.

Claims (7)

1. a gene association detection method, can detect KRAS, PIK3CA, BRAF and EGFR gene 16 kinds of sudden changes altogether simultaneously.
2. gene association detection method as claimed in claim 1, it is characterized in that, the sudden change of detection comprises:
KRAS gene mutation:
PIK3CA transgenation:
BRAF gene mutation: V600E (Cosmic ID 476)
EGFR genetic mutation: the deletion mutantion of 19 exons, L858R (Cosmic ID 6224, c.2573T>G) and T790M (Cosmic ID 6240, c.2369C>T).
3. gene association detection method as claimed in claim 1, is characterized in that, contain table 1middle P-SEQ-1 ~ P-SEQ-34 specific probe.
4. a gene association detection kit, is characterized in that, comprises specific probe described in claim 3.
5. a kind of gene association detection kit as claimed in claim 4, comprises following operation steps:
Template denaturation: added by template DNA in PCR pipe, is placed in PCR instrument, and set temperature is 95 ~ 100 DEG C, maintains 3 ~ 10min, then is cooled to 25 DEG C;
Hybridization: the mixture adding MLPA Buffer and probe in template after denaturing, the concentration of its middle probe is 0.5 ~ 10nM; Containing Tris-HCl (50 ~ 500mM, pH8.2 ~ 9.0) in MLPA Buffer, KCl (2 ~ 5M), MgCl2 (0.5 ~ 5M), EDTA (0.5 ~ 5mM); PCR instrument runs hybridization procedures: 95 DEG C of 1min; 60 DEG C of 16 ~ 24h;
Connect: after hybridization terminates, in each PCR pipe, add ultrapure water and ligase enzyme, PCR instrument runs linker: 50 ~ 58 DEG C of 10 ~ 30min; 95 ~ 100 DEG C of 10 ~ 30min; Be cooled to 20 DEG C;
Pcr amplification: ligation terminates the amplification of laggard performing PCR, adds PCR universal primer, dNTPs and Taq enzyme, PCR instrument is run PCR program in each PCR pipe;
Detect: the methods such as agarose electrophoresis, polyacrylamide gel electrophoresis and capillary electrophoresis can be adopted to detect the nucleic acid fragment of amplification.
6. a kind of gene association detection kit as claimed in claim 4, detected sample comprises fresh pathological tissue, paraffin embedding pathological tissue, paraffin section, saliva, sputum, urine and blood.
7. for detecting probes for KRAS, PIK3CA, BRAF and EGFR gene 16 kinds of sudden changes altogether, it is characterized in that, being made up of the oligonucleotide of at least 70% identity the oligonucleotide probe of P-SEQ-1 ~ P-SEQ-34 or sequence and its.
CN201410849552.XA 2014-12-30 2014-12-30 A kind of gene association detection method and test kit Active CN104480215B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410849552.XA CN104480215B (en) 2014-12-30 2014-12-30 A kind of gene association detection method and test kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410849552.XA CN104480215B (en) 2014-12-30 2014-12-30 A kind of gene association detection method and test kit

Publications (2)

Publication Number Publication Date
CN104480215A true CN104480215A (en) 2015-04-01
CN104480215B CN104480215B (en) 2016-12-07

Family

ID=52754817

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410849552.XA Active CN104480215B (en) 2014-12-30 2014-12-30 A kind of gene association detection method and test kit

Country Status (1)

Country Link
CN (1) CN104480215B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106566880A (en) * 2016-11-02 2017-04-19 哈尔滨星云生物信息技术开发有限公司 Hereditary hearing loss gene mutation detection kit
CN108118092A (en) * 2018-01-17 2018-06-05 王景杰 The processing method of polygene combined faeces DNA DNA methylation assay data
CN108287984A (en) * 2018-01-17 2018-07-17 张明鑫 The accurate processing method of polygene combined faeces DNA DNA methylation assay data
CN112553310A (en) * 2020-08-07 2021-03-26 中国医学科学院血液病医院(中国医学科学院血液学研究所) Method and kit for detecting cytogenetic abnormality by applying MLPA (MLPA)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRANCO-HERNANDEZ,C ET AL: "Gene dosage and mutational analyses of EGFR in oligodendrogliomas", 《INTERNATIONAL JOURNAL OF ONCOLOGY 》, vol. 30, no. 1, 31 December 2007 (2007-12-31) *
JEUKEN J ET AL: "Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors.", 《JOURNAL OF MOLECULAR DIAGNOSTICS 》, vol. 8, no. 4, 31 December 2006 (2006-12-31) *
WORSHAM MJ ET AL: "High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model.", 《BREAST CANCER RESEARCH AND TREATMENT 》, vol. 96, no. 2, 31 December 2006 (2006-12-31) *
胡佳莉等: "一种增强MLPA检测SNP位点的特异性方法", 《贵阳医学院学报》, vol. 37, no. 3, 31 December 2012 (2012-12-31) *
胡晓等: "多重连接依赖性探针扩增技术及其应用进展", 《现代生物医学进展》, vol. 10, no. 2, 31 December 2010 (2010-12-31) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106566880A (en) * 2016-11-02 2017-04-19 哈尔滨星云生物信息技术开发有限公司 Hereditary hearing loss gene mutation detection kit
CN108118092A (en) * 2018-01-17 2018-06-05 王景杰 The processing method of polygene combined faeces DNA DNA methylation assay data
CN108287984A (en) * 2018-01-17 2018-07-17 张明鑫 The accurate processing method of polygene combined faeces DNA DNA methylation assay data
CN112553310A (en) * 2020-08-07 2021-03-26 中国医学科学院血液病医院(中国医学科学院血液学研究所) Method and kit for detecting cytogenetic abnormality by applying MLPA (MLPA)

Also Published As

Publication number Publication date
CN104480215B (en) 2016-12-07

Similar Documents

Publication Publication Date Title
JP7256840B2 (en) Splice variants associated with neomorphic SF3B1 mutants
CN103114133B (en) Probe, primer and detection kit for detecting C-KIT gene mutation
US11180812B2 (en) Use of DNA in circulating exosomes as a diagnostic marker for metastatic disease
CN103382503B (en) EGFR gene 19 exon 19 kinds of deletion mutantion detection kit and detection method
CN101608240B (en) Primers and probes for detecting human EGFR gene mutations as well as use method thereof
JP2008529532A5 (en)
Siravegna et al. Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor
CN103923975A (en) Kit for detecting deletion mutation of EGFR gene exon 19, and method thereof
CN104480215B (en) A kind of gene association detection method and test kit
CN105002283A (en) QPCR composition used for detecting c-kit gene mutation of people and reagent kit
CN106148498A (en) KRAS gene mutation detection kit and application thereof
CN103773837A (en) Fluorescent quantitation PCR detection kit and detection method for PIK3CA (phosphatidylinositol3-kinase catalytic alpha) gene mutations
CN102399872B (en) Method and kit for detecting mutation of K-ras gene
CN105229171A (en) The method and composition of sudden change is detected in people PI3KCA (PIK3CA) gene
CN104263827A (en) Novel probe design method for ligase reaction
CN103013993B (en) The method of primer and this primer Mass Spectrometer Method PIK3CA hotspot mutation
CN102443626A (en) Detection kit for lung cancer driving gene mutation
CN103710443A (en) Detection primer set, detection kit and detection method of related SNP (single-nucleotide polymorphism) for causing CVM (complex vertebral malformation)
CN104805178A (en) TACC3-FGFR3 fused gene sequence and its detection method and use in bladder cancer detection
CN105969876B (en) Primer for detecting C-KIT gene mutation in microcomponent combines and its application
CN106011253A (en) Primer combination for detecting gene PDGFRA mutation in microtissue and application thereof
KR101388702B1 (en) Multiplex PCR primer set for detecting EGFR mutant and kit comprising the same
CN105969875B (en) Primer for detecting PIK3CA gene mutation in microcomponent combines and its application
CN105969874B (en) Primer for detecting KRAS gene mutation in microcomponent combines and its application
CN109811041A (en) A kind of specific primer detecting the site PIK3CA gene H1047R is to, probe and kit

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Zhou Xiwu

Inventor after: Tang Tao

Inventor before: Tang Tao

Inventor before: Zhou Xiwu

COR Change of bibliographic data
C14 Grant of patent or utility model
GR01 Patent grant
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Yu Ning

Inventor after: Liang Jianjia

Inventor after: He Fajian

Inventor after: He Xinliu

Inventor after: Liu Piqiong

Inventor before: Zhou Xiwu

Inventor before: Tang Tao

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20171214

Address after: 530000 the Guangxi Zhuang Autonomous Region Jiangnan District of Nanning goodcan Road No. 19 U lianxun Valley Science and Technology Park building A room 319

Patentee after: Nanning Wilke Biotechnology Co., Ltd.

Address before: 315040 business building, No. 66, academician Road, Ningbo, Zhejiang Province, 532

Patentee before: NINGBO UNIGENEDX BIO-PHARMACEUTICAL CO., LTD.